- Trial Phase
- Phase 2
- Time to Market
- At least 4-6 years away, if ever. Amgen is preparing Phase 3 registrational studies for DLE but has not announced a start date. Even after Phase 3 initiation, development, regulatory review, and potential approval would take several years.
- Why 3/10
- No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. Amgen is preparing Phase 3 registrational studies for DLE but has not announced a start date. Daxdilimab is a very small part of Amgen's massive, diversified portfolio (market cap ~$260B, dozens of marketed drugs). Even a best-case Phase 3 success would have a negligible impact on AMGN's share price.
The next catalyst is the initiation and enrollment of Phase 3 registrational trials for discoid lupus, which Amgen has signaled it is preparing but has not yet announced a timeline for. A successful Phase 3 program could open a first-in-class treatment for DLE, a niche with no approved biologics, but the drug's prior failure in SLE and the small addressable DLE market limit the commercial upside for a company of Amgen's scale.
Price Chart
Executive Summary
Daxdilimab is Amgen's investigational monoclonal antibody that depletes plasmacytoid dendritic cells (pDCs) by targeting the ILT7 receptor, reducing type I interferon production implicated in autoimmune diseases. It succeeded in a Phase 2 trial for discoid lupus erythematosus (DLE), meeting the primary endpoint with a 6-point CLASI-A reduction and 61.7% CLASI-50 response rate at the low dose, presented at EADV Congress in September 2026. However, it previously failed a Phase 2 trial in the larger systemic lupus erythematosus (SLE) indication. Amgen is preparing registrational (Phase 3) studies for DLE but has not announced a timeline. Daxdilimab is a very small part of Amgen's diversified portfolio, which includes dozens of marketed drugs and a deep pipeline.
How It Works
Daxdilimab is an antibody that targets and depletes plasmacytoid dendritic cells (pDCs), a type of immune cell that produces large amounts of type I interferons (proteins that drive inflammation). By binding to the ILT7 receptor found only on pDCs, it recruits natural killer cells to destroy these pDCs, reducing the inflammatory signals that fuel autoimmune diseases like lupus.
Trial Status
Phase 2 completed in discoid lupus erythematosus (DLE) with positive results presented at EADV Congress September 2026. Phase 2 failed in systemic lupus erythematosus (SLE). Phase 2 completed in dermatomyositis (too small to determine efficacy) and alopecia areata (modest signals). Amgen is preparing registrational (Phase 3) studies for DLE.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 3 registrational trial(s) for discoid lupus erythematosus (timeline TBD)
- Phase 2 dermatomyositis results (completed, small sample size, unclear next steps)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report